Trial of Roflumilast Cream for Chronic Plaque Psoriasis

• Published in: The New England journal of medicine Vol. 383; no. 3; pp. 229 - 239
• Main Authors: Lebwohl, Mark G, Papp, Kim A, Stein Gold, Linda, Gooderham, Melinda J, Kircik, Leon H, Draelos, Zoe D, Kempers, Steven E, Zirwas, Mathew, Smith, Kathleen, Osborne, David W, Trotman, Marie-Louise, Navale, Lynn, Merritt, Charlotte, Berk, David R, Welgus, Howard
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 16-07-2020
• Subjects: Administration, Topical; Adult; Aminopyridines - administration & dosage; Aminopyridines - adverse effects; Benzamides - administration & dosage; Benzamides - adverse effects; Clinical trials; Cyclopropanes - administration & dosage; Cyclopropanes - adverse effects; Cytokines; Double-Blind Method; Drug Administration Schedule; Enrollments; Erythema; Female; Humans; Immunoglobulin A; Least-Squares Analysis; Male; Middle Aged; Patients; Phosphodiesterase; Phosphodiesterase 4 Inhibitors - administration & dosage; Phosphodiesterase 4 Inhibitors - adverse effects; Phosphodiesterase IV; Psoriasis; Psoriasis - drug therapy; Severity of Illness Index; Skin; Skin Cream - administration & dosage; Canada; United States > US
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa2000073

A cream formulation of the phosphodiesterase type 4 inhibitor roflumilast, in two concentrations, led to higher percentages of patients with clearance or near-clearance of psoriatic lesions at 6 weeks than placebo. Difficult-to-treat intertriginous areas also improved as compared with placebo.